247 related articles for article (PubMed ID: 9582019)
1. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
2. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
[TBL] [Abstract][Full Text] [Related]
4. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Somasundaram K; Zhang H; Zeng YX; Houvras Y; Peng Y; Zhang H; Wu GS; Licht JD; Weber BL; El-Deiry WS
Nature; 1997 Sep; 389(6647):187-90. PubMed ID: 9296497
[TBL] [Abstract][Full Text] [Related]
5. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Lu M; Arrick BA
Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Somasundaram K; MacLachlan TK; Burns TF; Sgagias M; Cowan KH; Weber BL; el-Deiry WS
Oncogene; 1999 Nov; 18(47):6605-14. PubMed ID: 10597265
[TBL] [Abstract][Full Text] [Related]
7. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
11. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
[TBL] [Abstract][Full Text] [Related]
12. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
13. A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Buck M
Cancer Lett; 2008 Sep; 268(1):137-45. PubMed ID: 18501503
[TBL] [Abstract][Full Text] [Related]
14. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Abramovitch S; Werner H
Horm Metab Res; 2003; 35(11-12):758-62. PubMed ID: 14710355
[TBL] [Abstract][Full Text] [Related]
15. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
[TBL] [Abstract][Full Text] [Related]
16. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
17. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
[TBL] [Abstract][Full Text] [Related]
20. c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells.
Ceballos E; Delgado MD; Gutierrez P; Richard C; Müller D; Eilers M; Ehinger M; Gullberg U; León J
Oncogene; 2000 Apr; 19(18):2194-204. PubMed ID: 10822369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]